Prognostic Value of SPARC Expression in Unresectable NSCLC Treated with Concurrent Chemoradiotherapy

Creative Commons License

Kurtul N., EROĞLU C., Unal D., Tasdemir E. A., ORHAN O., ZARARSIZ G., ...More

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.20, pp.8911-8916, 2014 (SCI-Expanded) identifier identifier


Background: The aim of the present study was to determine the predictive/prognostic value of the secreted protein, acidic and rich in cysteine (SPARC) in cases of unresectable, locally advanced, non-small cell lung cancer. Materials and Methods: The study included 84 patients with Stage IIIA-B non-small cell lung cancer, undergoing simultaneous chemoradiotherapy including radiotherapy at a dose of 66 Gy and weekly docataxel (20 mg/m(2)) and cisplatin (20mg/m(2)). SPARC expression was studied in biopsy material by immunohistochemical methods and correlations with treatment responses or survival were evaluated. Results: Median overall survival was 16 +/- 2.73 (11.55-20.46) months for low expression vs 7 +/- 1.79 months (7.92-16.08) months for high expression (p=0.039), while median local control was 13 +/- 2.31 (8.48-17.5) months for low expression vs 6 +/- 0.85 (4.34-7.66) months for high expression (p=0.045) and median progression-free survival was 10 +/- 2.31 (5.48-14.5) months for low expression vs 6 +/- 1.10 (3.85-8.15) months for high expression (p=0.022). In both univariate and multivariate analyses, high SPARC expression was associated with significantly shorter overall survival (p=0.003, p=0.007, respectively), local control (p=0.008, p=0.036) and progression-free survival (p=0.004, p=0.029) when compared to low SPARC expression. No significant difference was detected between high and low SPARC expression groups regarding age, sex, T stage, N stage, histopathology and stage-related patient characteristics. Conclusions: High SPARC expression was identified as a poor prognostic factor in cases with locally advanced NSCLC treated with concurrent chemoradiotherapy.